Q-omics provides the consensus-scored C17orf80 profile across patient tissues and cancer cell-line models. C17orf80 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, C17orf80 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, C17orf80 RNA expression shows 21,431 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, HNSC, and ACC as cancer lineages where C17orf80 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C17orf80 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C17orf80 survival associations across molecular data types. C17orf80 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C17orf80 RNA expression–survival associations across cancer types. High C17orf80 expression shows unfavorable associations in LIHC and ACC, but favorable associations in KIRC, THYM, BRCA and COAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for C17orf80 RNA expression.
This table summarizes C17orf80 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for C17orf80. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C17orf80 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, LUAD and KIRP. The HNSC box plot shows higher C17orf80 RNA expression in tumor versus normal tissue (log2 FC = +0.750, t-test p < 0.001).
This table shows molecular features associated with C17orf80 in patient tissues and cancer cell lines. In patient samples, C17orf80 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, C17orf80 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
